Xin Hui Chan
Xin Hui Chan
BMBCh MA MSc DPhil MRCP DTM&H DipRCPath
NIHR Academic Clinical Lecturer in Infectious Diseases
- Honorary Specialty Registrar in Infectious Diseases and General Internal Medicine
CLINICAL THERAPEUTICS FOR EMERGING INFECTIOUS DISEASES
Dr Xin Hui Chan is an NIHR Academic Clinical Lecturer in Infectious Diseases at the University of Oxford and an Honorary Specialty Registrar in Infectious Diseases and General Internal Medicine at Oxford University Hospitals. Her current research focuses on accelerating the equitable development of clinical therapeutics for high-threat and emerging infectious diseases such as Nipah and dengue.
She leads a programme of work combining evidence synthesis, clinical trials, systems pharmacology, statistical modelling, and qualitative methods to optimise how we develop and deploy therapeutic interventions for the world's deadliest - and most neglected - infections.
She is a member of the UK Health Security Agency Malaria Expert Advisory Group and serves on the Editorial Boards of Travel Medicine and Infectious Disease and PLOS Global Public Health.
Xin Hui trained in medicine, infectious diseases, and tropical medicine in Oxford, London (LSHTM & University College London Hospitals), and Southeast Asia with further experience in North America (US National Institutes of Health), sub-Saharan Africa (MRC Unit The Gambia), and Southeastern Europe.
Her UK MRC-funded DPhil with Prof Sir Nick White at the Mahidol-Oxford Tropical Medicine Research Unit (MORU) was a global evidence review of the cardiovascular safety of antimalarial medicines to optimise their development and deployment in collaboration with the WHO Global Malaria Programme. She was the WHO technical resource person and rapporteur of the WHO Evidence Review Group on the Cardiotoxicity of Antimalarial Medicines.
Recent publications
-
Autochthonous Human Babesia divergens Infection, England
Journal article
Zabala GA. et al, (2024), Emerging Infectious Diseases, 30
-
Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial
Journal article
Faust SN. et al, (2024), The Lancet Child & Adolescent Health
-
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Journal article
Abani O. et al, (2023), The Lancet Diabetes & Endocrinology, 11, 905 - 914
-
Factors that impact on recruitment to vaccine trials in the context of a pandemic or epidemic: a qualitative evidence synthesis.
Journal article
Meskell P. et al, (2023), The Cochrane database of systematic reviews, 9
-
Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
Journal article
Abani O. et al, (2023), The Lancet, 401, 1499 - 1507